List of Zynrelef Kit drug patents
Zynrelef Kit is owned by Heron Theraps Inc.
Zynrelef Kit contains Bupivacaine; Meloxicam.
Zynrelef Kit has a total of 15 drug patents out of which 0 drug patents have expired.
Zynrelef Kit was authorised for market use on 12 May, 2021.
Zynrelef Kit is available in solution, extended release;periarticular dosage forms.
Zynrelef Kit can be used as treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation, treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation.
The generics of Zynrelef Kit are possible to be released after 20 April, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
| US10632199 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10980886 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2035
(12 years from now) | |
| US11413350 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US9694079 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US9801945 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10213510 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| US10098957 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 12, 2024 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation; Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
ZYNRELEF KIT family patents
29
United States
12
Japan
6
China
6
European Union
5
Korea, Republic of
5
Australia
3
Canada
2
RS
2
Poland
2
Lithuania
2
Spain
2
Mexico
2
Slovenia
2
Hungary
2
Portugal
2
Croatia
2
Taiwan, Province of China
2
Denmark
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic